
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Amphetamine, Dextroamphetamine Mixed Salts (Adderall)
Atomoxetine
Methylphenidate Hydrochloride (Concerta, ER)
Dexmethylphenidate Hydrochloride (Focalin)






